Medical Device Trials: Patient Recruitment Differences?
Praxis' director of marketing, Chris Layfield, offers insight into patient recruitment and developing a strategic recruitment plan when conducting medical device trials.
Medical Device Trials: Patient Recruitment Differences?
Chris Layfield, director of marketing at Brentwood, TN-based Praxis, told Applied Clinical Trials, “Like any trial, pharmaceutical or device, the process to developing a strategic recruitment plan is the same. One must fully understand the protocol and devise procedures to the extent that an accurate patient profile can be established. Without this, one cannot hope to effectively create a targeted reach program.”
Layfield explained after that is established, the appropriate primary, secondary and experiential research is done to determine how best to reach the persons identified in the profile – those that will be the most likely candidates for trial participation. Layfield offered this example; an acute situation where a new implantable device is being tested in heart attack patients. “If the decision to try the new device were to be needed within several hours or even less after a heart procedure then, information needs to be available to the treating physician and the family of the candidate at the time they present at the ER.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
